Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04225039).
- Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection: Complete Statistical AnalysisIndependent statistical analysis of Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection: primary endpoint…
- Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01112293).
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: Complete Statistical AnalysisIndependent statistical analysis of Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003508).
- Antineoplaston Therapy in Treating Patients With Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003483).
- Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ANVILIndependent statistical analysis of the ANVIL phase 3 trial of nivolumab after surgery and chemotherapy in patients with stage IB-IIIA non-small cell lung cancer, including trial design, disease-free survival and overall survival…
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer: Complete Statistical AnalysisIndependent statistical analysis of APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- APP21Independent statistical analysis of Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- APP22Independent statistical analysis of Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Application of 3D Printing Technique in Small Pulmonary Nodule Localization: Complete Statistical AnalysisIndependent statistical analysis of Application of 3D Printing Technique in Small Pulmonary Nodule Localization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02952261).
- APPRISE 1Independent statistical analysis of Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- APTIndependent statistical analysis of the APT phase 1/2 study of AP203 in patients with locally advanced or metastatic solid tumors, including trial design, endpoints, planned statistical methods, interpretation, and limitations.
- ARAMISIndependent statistical analysis of the phase 3 ARAMIS trial of darolutamide versus placebo in men with high-risk non-metastatic castration-resistant prostate cancer, including metastasis-free survival, overall survival, time-to-event methods, and statistical interpretation.
- ARASENSIndependent statistical analysis of ARASENS, the randomized phase 3 trial of darolutamide plus standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer, including time-to-event methodology, reported hazard ratios, confidence intervals,…
- ARC-7An independent statistical analysis of ARC-7, a randomized phase 2 trial evaluating monotherapy and combination immunotherapies in participants with PD-L1 positive non-small cell lung cancer.
- ARCADIANIndependent statistical analysis of Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04648033).
- ARIEL3Independent statistical analysis of the phase 3 ARIEL3 trial of rucaparib as switch maintenance after platinum in relapsed high-grade serous or endometrioid ovarian cancer, including trial design, progression-free survival, Cox modeling, hazard…
- Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ARTEMISAn independent statistical analysis of the randomized phase 3 ARTEMIS trial evaluating bevacizumab in combination with erlotinib versus erlotinib alone in patients with NSCLC harbouring activating EGFR mutations.
- ASACIndependent statistical analysis of ASAC (NCT03326791), a randomized phase 2/3 trial evaluating acetylsalicylic acid versus placebo after resection of colorectal cancer liver metastases, with emphasis on disease-free survival and its planned analysis.
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ASCENTIndependent statistical analysis of A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation: Complete Statistical AnalysisIndependent statistical analysis of Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer: Complete Statistical AnalysisIndependent statistical analysis of Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion: Complete Statistical AnalysisIndependent statistical analysis of Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca: Complete Statistical AnalysisIndependent statistical analysis of Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas: Complete Statistical AnalysisIndependent statistical analysis of Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03371485).
- ASTECA detailed statistical analysis and educational interpretation of the ASTEC phase 3 randomized trial of surgery with or without lymphadenectomy and radiation therapy in patients with endometrial cancer.
- ASTEROID 1Independent statistical analysis of Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02131662).
- ATACIndependent statistical analysis of the ATAC phase 3 clinical trial (NCT00784940), including trial design, endpoints, planned statistical methods, and educational interpretation.
- ATALANTE-1Independent statistical analysis of OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site: primary endpoint results, effect estimate with…
- Atezolizumab Immunotherapy in Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab Immunotherapy in Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03102242).
- ATLANTIndependent statistical analysis of Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy: primary endpoint results, effect estimate…
- AtTEndIndependent statistical analysis of the phase 3 AtTEnd trial of atezolizumab in endometrial cancer, covering trial design, progression-free survival, overall survival, planned statistical methods, and interpretation.
- aTTomIndependent statistical analysis of the phase 3 aTTom trial of tamoxifen as adjuvant therapy in women with breast cancer, including trial design, the registered all-cause mortality endpoint, planned statistical analysis, and interpretation.
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…